文献速递神经免疫

奥瑞珠单抗治疗复发型和原发进展型多发性硬化长达7年的安全性

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
PubMed 文献 · Neurology · 2021-09-02

该分析基于11项临床试验中接受奥瑞珠单抗(OCR)治疗的5680例多发性硬化患者(共18218患者年暴露),截至2020年1月数据截止,严重感染和恶性肿瘤发生率与流行病学数据范围一致;真实世界用药超过3年也未发现新的安全性问题,总体安全性良好且可控。

要点

  • 临床试验中OCR暴露长达7年,真实世界使用超过3年,安全谱一致且可控。
  • 每100患者年的严重感染率为2.01(95%CI 1.81-2.23),与流行病学数据相符。
  • 每100患者年的恶性肿瘤率为0.46(95%CI 0.37-0.57),未超出预期范围。

核心结论

  • 在异质性多发性硬化人群中,OCR连续治疗长达7年及真实世界使用超过3年,安全性良好且可控,未出现新的安全信号。

研究设计与样本

  • 基于11项临床试验(含2/3期对照期和开放标签扩展期及多项3b期试验)中所有接受OCR治疗患者的整合临床和实验室数据。
  • 共纳入5680例多发性硬化患者,累计18218患者年暴露;部分不良事件补充了上市后数据。

主要发现

  • 每100患者年的不良事件率为248(95%CI 246-251),严重不良事件为7.3(95%CI 7.0-7.7)。
  • 每100患者年的输液相关反应率为25.9(95%CI 25.1-26.6),感染率为76.2(95%CI 74.9-77.4)。
  • 最常见的严重不良事件包括严重感染(每100患者年2.01,95%CI 1.81-2.23)和恶性肿瘤(每100患者年0.46,95%CI 0.37-0.57),均与流行病学数据范围一致。

关键数值与推荐

  • 严重感染发生率2.01/100患者年(95%CI 1.81-2.23),与多个流行病学来源范围一致。
  • 恶性肿瘤发生率0.46/100患者年(95%CI 0.37-0.57),与流行病学数据相符。

临床怎么用

  • 对于复发型和原发进展型多发性硬化患者,长期使用OCR的安全性与已知特征一致,无需因新发安全信号调整监测策略。

局限性

  • 证据等级为Class III,因使用开放标签扩展数据及历史对照而受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To report safety of ocrelizumab (OCR) up to 7 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) enrolled in clinical trials or treated in real-world postmarketing settings. METHODS: Safety analyses are based on integrated clinical and laboratory data for all patients who received OCR in 11 clinical trials, including the controlled treatment and open-label extension (OLE) periods of the phase 2 and 3 trials, plus the phase 3b trials VELOCE, CHORDS, CASTING, OBOE, ENSEMBLE, CONSONANCE, and LIBERTO. For selected adverse events (AEs), additional postmarketing data were used. Incidence rates of serious infections (SIs) and malignancies were contextualized using multiple epidemiologic sources. RESULTS: At data cutoff (January 2020), 5,680 patients with multiple sclerosis (MS) received OCR (18,218 patient-years [PY] of exposure) in clinical trials. Rates per 100 PY (95% confidence interval) of AEs (248; 246-251), serious AEs (7.3; 7.0-7.7), infusion-related reactions (25.9; 25.1-26.6), and infections (76.2; 74.9-77.4) were similar to those within the controlled treatment period of the phase 3 trials. Rates of the most common serious AEs, including SIs (2.01; 1.81-2.23) and malignancies (0.46; 0.37-0.57), were consistent with the ranges reported in epidemiologic data. DISCUSSION: Continuous administration of OCR for up to 7 years in clinical trials, as well as its broader use for more than 3 years in the real-world setting, are associated with a favorable and manageable safety profile, without emerging safety concerns, in a heterogeneous MS population. CLASSIFICATION OF EVIDENCE: This analysis provides Class III evidence that long-term, continuous treatment with OCR has a consistent and favorable safety profile in patients with RMS and PPMS. This study is rated Class III because of the use of OLE data and historical controls.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hauser SL, Kappos L, Montalban X, et al. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology. 2021. PMID: 34475123. doi:10.1212/WNL.0000000000012700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。